All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.

  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub
Brought to you by Scientific Education Support

The MPN Hub is an independent medical education platform, sponsored by GSK, Novartis, AOP, Sobi and Takeda and supported through independent educational grants from Bristol Myers Squibb, Blueprint Medicines, Incyte and Merck Sharp & Dohme LLC, Rahway, NJ, USA. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

#ASCO23

Share:

Jun 2, 2023

X post image

6 Jun 2023

CONGRESS |#ASCO23 |Francesco Passamonti shared preliminary data from ARM 4 of the MANIFEST trial. Pelabresib resulted in hematologic responses & improved symptoms in pts with HR-ET and R/R to hydroxyurea; it demonstrated a consistent safety profile to previous studies
#MPN #MPNsm

View on 

X post image

6 Jun 2023

CONGRESS| #ASCO23 | Helen Ajufo from @MSKCancerCenter presented analyzed data from the PERSIST-2 trial showing that spleen volume reduction is associated with a survival benefit in pts with MF treated on pacritinib but not on best available therapy
#MPNsm #medicalcongress

View on 

X post image

6 Jun 2023

CONGRESS|#ASCO23|@bose_prithviraj @MDAndersonNews showcased the phase 1/2 study results of ALK-2 inhibitor zilurgisertib alone or with RUX in pts with anemia due to MF. It was well tolerated with no DLTs & mostly Grade 1/2 TEAS and reduced hepecidin levels across all doses
#MPNsm

View on 

X post image

6 Jun 2023

CONGRESS| #ASCO23| @AaronGerds @caseccc shared efficacy and safety results of the ACE-536-MF-001 study. Luspatercept improved anemia across all cohorts with MF regardless of transfusion status or the use of RUX, and had a consistent safety profile to previous studies
#MPNsm

View on 

X post image

6 Jun 2023

CONGRESS|#ASCO23|Yi Zhang summarized phase 3 data on jaktinib vs hydroxyurea (HU) in pts with intermediate-2 or HR-MF. Compared to HU, jaktinib showed clinical benefits in spleen & symptom response, representing a new treatment option for MF pts incl those with anemia
#MPNsm

View on 

X post image

5 Jun 2023

CONGRESS|#ASCO23|@JustinWattsMD, @SylvesterCancer presents the preliminary phase I results on BET inhibitor INCB057643 alone or combined with ruxolitinib in pts with R/R MF,MDS & MDS/MPN. It was well tolerated alone (4&8mg,QD) or combined (4mg,QD) and demonstrated efficacy
#MPN

View on 

X post image

5 Jun 2023

CONGRESS| #ASCO23 | Poster
Prithviraj Bose (@bose_prithviraj) of @MDAndersonNews describes data across PERSIST-1 and PERSIST-2 trials showing the consistent efficacy of pacritinib for spleen reduction and symptom improvements in pts with MF regardless of cytopenias
#MPN #MPNsm

View on 

X post image

5 Jun 2023

CONGRESS|#ASCO23|Ruben Mesa (@mpdrc), @UTHealthSAMDA reports data from the post hoc analyses of SIMPLIFY-1 and 2 showing lower functioning and lower HRQOL in transfusion-dependent vs transfusion independent pts with MF, highlighting the impact of transfusion status on PROs
#MPN

View on 

X post image

5 Jun 2023

CONGRESS| #ASCO23 | @Mdmasarova, @MDAndersonNews presents data from an ITC safety analysis of momelotinib vs fedratinib in JAKi-experienced/naïve pts with MF from phase 2 or 3 trials. Momelotinib had a more favorable safety profile, with a lower risk of key hematologic AEs
#MPNsm

View on 

X post image

5 Jun 2023

CONGRESS | #ASCO23| Poster
Ciro Rinaldi (@tamaciro) of @unilincoln shared insights into the invitro effects of ruxolitinib and magrolimab reducing overall cell survival rate in CD34+ MF samples, and significantly increasing calreticulin expression
#MPN #MPNsm #medicalcongress

View on 

X post image

5 Jun 2023

CONGRESS|#ASCO23|Poster
Haris Ali @MPN_BMTDOC, @cityofhope presents the updated XPORT-MF-034 trial results showing that 60mg selinexor plus ruxolitinib demonstrated rapid and deep spleen responses across all subgroups, and was well tolerated in treatment-naïve pts with MF
#MPNsm

View on 

X post image

5 Jun 2023

CONGRESS | #ASCO23 | Poster
Jie Jin @ZJU_China summarizes the efficacy and safety of jaktinib in pts with MF who were R/R to ruxolitinib. It substantially improved splenomegaly & reduced MF-related symptoms, thus representing a new treatment option for this pt subset
#MPN #MPNsm

View on 

X post image

5 Jun 2023

CONGRESS |#ASCO23 | POSTER
Yi Zhang presents a nice summary on the efficacy and safety of jaktinib in patients with MF who were intolerant to ruxolitinib showing promising clinical activity - reduced splenomegaly, improved symptom burden and anemia
#MPNsm #medicalcongress

View on 

X post image

5 Jun 2023

CONGRESS| #ASCO23 @Mdmasarova @MDAndersonNews reviews the need for treatment in patients with ET, with none approved in the past decade. The EXCEED-ET study will evaluate the efficacy and safety of ropeginteferon alfa-2b-njft in the treatment of adult patients with ET. #MPNsm

View on 

X post image

5 Jun 2023

CONGRESS| #ASCO23 @Mdmasarova @MDAndersonNews summarizes an ongoing study of patients with MF who are being treated with ruxolitinib+CXCR4 enriched Tregs (CK0804). A combined treatment might improve clinical outcomes for patients with suboptimal response to ruxolitinib #MPN

View on 

X post image

5 Jun 2023

CONGRESS| #ASCO23 Jan Bewersdorf @MSKCancerCenter discusses the poor prognosis of ruxolitinib (median OS: 13 months) in patients with MF who discontinue treatment due to AEs or lack of response. A new study will evaluate MTD of ruxolitinib + abemaciclib in patients with MF #MPNsm

View on 

X post image

5 Jun 2023

CONGRESS|#ASCO23 @LeivaOrly @NYUgrossman discusses the association between thrombotic and bleeding outcomes in 468 094 patients with AF and a history of MPN. MPN was associated with increased risk of 30-day bleeding readmissions despite similar HAS-BLED risk scores #MPNsm

View on 

X post image

1 Jun 2023

🗣 The #MPN Hub will be virtually covering the 2023 ASCO Annual Meeting on June 2–6.

Keep an eye on our socials for live updates throughout the congress! 

#MPNsm #ASCO23 #cancertreatment #hematology

View on 

<span>&nbsp;</span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ASCO 2023American Society of Clinical Oncology

Your opinion matters

Do you include basal serum tryptase (bST) testing in the diagnostic evaluation of patients with MPN?

Newsletter

Subscribe to get the best content delivered to your inbox